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Background
The manufacture of a majority of clinical T cell pro-
ducts for immunotherapy applications requires in vitro
T cell culture and expansion. Commercialization of
T cell manufacturing processes requires reagents that
meet regulatory guidelines and ultimately help reduce
manufacturing cost of goods. A key component in many
T cell culture protocols is human serum, which is
expensive and requires extensive testing prior to use for
the manufacture of cGMP-compliant T cell therapies.
To this end, we have developed a xeno-free serum
replacement, CTS™ Immune Cell SR, with defined
components that can be used in combination with mul-
tiple cell culture media to support in vitro expansion of
functionally intact T cells.
Results
T cells activated and expanded with Dynabeads® CD3/
CD28 CTSTM and cultured in CTS™ OpTmizer™ T cell
Expansion SFM, X-VivoTM 15, or CTS™AIM-V® supple-
mented with pooled human serum or serum free CTS™
Immune Cell SR showed similar growth kinetics, total fold
expansion and transduction efficiency after 2 weeks in cul-
ture. Numbers of CD4+ and CD8+ T cells were compar-
able in cultures expanded with media containing human
serum or CTS™ Immune Cell SR. T cells demonstrated
efficacy when infused in an in vivo leukemia mouse model.
T cell engraftment and leukemia control were similar
between mice treated with T cells grown in media con-
taining human serum or CTS™ Immune Cell SR.
Conclusions
These studies demonstrate that human serum may be
replaced by a xeno-free formulation in combination
with several commonly used T cell culture media to
support in vitro expansion and lentiviral transduction of
polyclonal T cells. Culturing T cells in CTS™ Immune
Cell SR facilitates a favorable culture profile and
immune function. Serum free CTS™ Immune Cell SR
contains only fully tested human-derived or human
recombinant proteins which facilitates supply security
for large-scale production of clinical and commercial
therapies.
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